|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-4-6
|
|
pubmed:abstractText |
FB2 is a novel Abl/Src dual tyrosine kinase inhibitor which is designed to overcome imatinib resistance. Besides imatinib-sensitive cell lines (K562), FB2 significantly inhibited the growth of imatinib-resistant cell lines of different resistance mechanisms (K562/G5.0 and K562/G01), and decreased the expression of autophosphorylation of Bcr/Abl, c-Src and Lyn kinases on them. It also inhibited the proliferation of Src over activated cells DU145 and MDA-MB-231. Furthermore, FB2 potently prolonged the survival time of non-obese diabetic/severe combined immunodeficient mice harboured K562/G5.0 cells. These results indicated that FB2, an Abl/Src dual tyrosine kinase inhibitor, is a promising candidate for imatinib-resistant CML and Src over activated cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1029-2403
|
|
pubmed:author |
pubmed-author:ChenXiaoguangX,
pubmed-author:FengZhiqiangZ,
pubmed-author:LiHongyanH,
pubmed-author:LiuHeH,
pubmed-author:MingxinZuoZ,
pubmed-author:SunM FMF,
pubmed-author:WangHongboH,
pubmed-author:XinHongqiH,
pubmed-author:YangMengM,
pubmed-author:ZhangSenS,
pubmed-author:ZhangYanY
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
50
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
437-46
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:19347730-Animals,
pubmed-meshheading:19347730-Antineoplastic Agents,
pubmed-meshheading:19347730-Drug Resistance, Neoplasm,
pubmed-meshheading:19347730-Humans,
pubmed-meshheading:19347730-K562 Cells,
pubmed-meshheading:19347730-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:19347730-Mice,
pubmed-meshheading:19347730-Mice, SCID,
pubmed-meshheading:19347730-Phosphorylation,
pubmed-meshheading:19347730-Piperazines,
pubmed-meshheading:19347730-Protein Kinase Inhibitors,
pubmed-meshheading:19347730-Proto-Oncogene Proteins c-abl,
pubmed-meshheading:19347730-Pyrimidines,
pubmed-meshheading:19347730-Survival Rate,
pubmed-meshheading:19347730-Xenograft Model Antitumor Assays,
pubmed-meshheading:19347730-src-Family Kinases
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro.
|
|
pubmed:affiliation |
Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
|
|
pubmed:publicationType |
Journal Article
|
